Lisata Therapeutics
LSTA
21 hedge funds and large institutions have $1.46M invested in Lisata Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 2 reducing their positions, and 4 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
0.13% less ownership
Funds ownership: 8.54% → 8.41% (-0.13%)
5% less funds holding
Funds holding: 22 → 21 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
42% less capital invested
Capital invested by funds: $2.51M → $1.46M (-$1.05M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$48.4K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$26.8K |
| 3 |
Renaissance Technologies
New York
|
+$6.67K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.9K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$394 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$55.3K |
| 2 |
Morgan Stanley
New York
|
-$30.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.92K |
| 4 |
VNA
Valley National Advisers
Bethlehem,
Pennsylvania
|
-$1K |
| 5 |
Barclays
London,
United Kingdom
|
-$64 |
LSTA Hedge Fund Activity: Q3 2023 in Review
21 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q3 2023, worth a combined $1.46M — down 42% from $2.51M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LSTA and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 8 added.
The largest buyer was Geode Capital Management, adding an estimated $48.4K. The largest seller was Dimensional Fund Advisors, exiting entirely with an estimated $55.3K sold.
- 21 institutional investors held Lisata Therapeutics (LSTA) as of Q3 2023, down from 22 in Q2 2023.
- Funds reported $1.46M of Lisata Therapeutics stock for Q3 2023, down 42% quarter-over-quarter.
- 3 funds opened new Lisata Therapeutics positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest Lisata Therapeutics buyer in Q3 2023 was Geode Capital Management, an estimated $48.4K added.
- The largest Lisata Therapeutics seller in Q3 2023 was Dimensional Fund Advisors, an estimated $55.3K sold.
Based on aggregated 13F filings for Q3 2023.